Objective. Chronic pain conditions profoundly affect the daily living of a significant number of people and are a major economic and social burden, particularly in developing countries. The Change Pain Latin America (CPLA) advisory panel aimed to identify the most appropriate guidelines for the treatment of neuropathic pain (NP) and chronic low back pain (CLBP) for use across Latin America.
Google. Articles were screened by an independent reviewer, and potential candidate guidelines were selected for more in-depth review. A shortlist of suitable guidelines was selected and critically evaluated by the CPLA advisory panel.
Results. Searches identified 674 and 604 guideline articles for NP and CLBP, respectively. Of these, 14 guidelines were shortlisted for consensus consideration, with the following final selections made:
Introduction
Chronic pain conditions affect a significant number of people, have a profound negative impact on quality of life (QoL), and markedly impair daily function. Globally, the direct and indirect economic cost of chronic pain is estimated to equal that of cancer and cardiovascular disease, and the social burden is particularly great in developing countries [1] .
In Latin America, chronic pain is often undiagnosed and may be treated inappropriately or inadequately because of a wide range of barriers to best practice, such as limited access to medications and pain specialists in some countries [2] . In addition, there are gaps in the understanding of many pain conditions and widespread misconceptions regarding treatment [2] ; therefore, there is a need for improved education and adoption of uniform management guidelines.
Neuropathic pain (NP) and chronic low back pain (CLBP) are two of the most common types of chronic pain, and there is a clear requirement for these conditions to be better managed across Latin America.
NP is defined as "pain arising as a direct consequence of a lesion or disease affecting the somatosensory system" [3] . NP is characterized by abnormal somatosensory processing that occurs in the normal nociceptive system after injury [3] and can arise from a wide range of disorders, including painful diabetic neuropathy, postherpetic neuralgia, and trigeminal neuralgia [4] .
In a Brazilian epidemiological study, the prevalence of chronic pain with neuropathic characteristics was 10% in the study population [5] . According to the Latin American Federation of Associations for the Study of Pain, the most frequent cause of NP in Latin America was lumbago with a neuropathic component (34% of patients) [6] .
Due to the complexity of diagnosing and managing NP and its low prioritization in Latin American health care systems, it is associated with significant direct medical costs and a high overall economic and societal burden [7] . Of note, individuals reporting chronic pain with NP symptoms reported a higher prevalence of moderate or high pain intensity, disability resulting from pain, and depression than those with chronic pain without NP symptoms [5] .
CLBP is defined as pain that has persisted for more than three months and is localized below the lower edge of the last rib and above the lower gluteal folds, with or without a neuropathic component [8] . CLBP is generally multifactorial, often including a neuropathic component [9] , and is frequently under-recognized and undertreated [10, 11] . Where there is neuropathic involvement, CLBP is associated with severe symptoms [11] , comorbidities, and poor QoL.
Globally, CLBP causes more disability than any other condition [12] and is estimated to lead to direct and indirect costs of approximately 1.7% of the gross national product of a developed country [13] . In Latin America, the prevalence of CLBP has been estimated at 11% [8] , accounting for 10% to 15% of all disability claims in Mexico [14] , while CLBP is the third most common cause of employment-associated disability in Argentina [15] . In Brazil, back pain is the most common cause of permanent, pensionable disability, accounting for 97% of working days lost due to disability [16] .
Change Pain Latin American (CPLA) is a new initiative committed to enhancing the QoL of chronic pain patients (Table 1) [2] . It was launched in response to a similar educational campaign that has improved chronic pain management throughout Europe.
Although many chronic pain management guidelines have been published, none completely satisfies the specific requirements of Latin America. Therefore, we set out to identify the most appropriate guidelines for NP and CLBP that are applicable to the Latin American region. This article summarizes the group's consensus and aims to provide a platform for the implementation and adoption of uniform management guidelines by health care practitioners across the Latin American region.
Methods
The CPLA advisory panel comprises 17 Latin American experts from Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, Peru, Venezuela, and Spain who specialize in pain management across a range of clinical fields [2] . The panel convened at four meetings to discuss the need for a uniform set of management guidelines and to develop the methodology used to identify the guidelines most appropriate for the region.
Search Strategy
A systematic search for published guidelines was conducted using defined search terms (Table 2) . For systematic reviews or practice guidelines, the PubMed search engine was employed using English and Spanish search terms. For evidence-based clinical practice guidelines, the National Guideline Clearinghouse database was searched, and additional searches were performed using the Google search engine in order to identify additional guidelines that were not indexed by other sources.
Preliminary Analysis
Extracted articles were screened by an independent reviewer according to a set of previously agreed-upon preliminary analysis criteria (Table 3) . Guidelines considered to be potential candidates for adoption were identified based on this initial evaluation.
Guidelines were considered to be evidence based if their recommendations were based on published clinical trial data, as opposed to treatment recommendations based on physicians' experience or opinion. A source was considered to be well recognized if it was published in a peer-reviewed journal or on the website of a recognized physician association.
The reviewer's opinion on the applicability of guidelines was based on their clinical experience in pain management in Latin America and a range of objective factors, including whether a guideline recommended unavailable, infeasible, or costly treatments, therapies requiring resource-intensive administration or monitoring, or interventions requiring specialist skills.
Secondary Analysis
Candidate guidelines selected for further investigation during the initial screening were analyzed in depth, and a shortlist of guidelines suitable for consideration was selected based on a set of key selection criteria (Table 3) .
Tertiary Analysis
As a final step in the selection process, shortlisted guidelines for NP and CLBP were assessed by the expert panel for relevance, validity, and practicality. The guidelines that best met these criteria were then presented at the CPLA advisory panel meeting, where each was considered at length in the context of current practice in Latin America.
Consensus Agreement
The CPLA advisory panel employed a process of consensus discussion and agreement in order to reach single guideline recommendations for NP and CLBP. At this meeting, all panelists formally ratified the recommendations, and each panelist was invited to add additional consideration points relevant to their country.
Results
The initial PubMed search identified 674 systematic reviews or practice guidelines for NP and 604 systematic reviews or practice guidelines for CLBP. Following the initial screening, 28 guidelines (18 NP, 10 CLBP) were selected as candidates for in-depth review by the CPLA expert panel. The candidate guidelines were narrowed down to a shortlist of eight NP and six CLBP management guidelines for further appraisal and consensus consideration (Table 4) .
At the end of the final stage of discussion and debate, a single management guideline recommendation was identified for each condition, with seven of the shortlisted NP guidelines and five of the shortlisted CLBP guidelines considered to be unsuitable for adoption in the Latin American region (Supplementary Table S1 ).
By consensus agreement, we endorsed the following guidelines as the best fit for use across Latin America:
• "Recommendations for the pharmacological management of neuropathic pain: An overview and literature update: International Association for the Study of Pain Neuropathic Pain Special Interest Group (IASP NeuPSIG) 2010 guidelines" [19] . The 2015 revision of these recommendations, based on a recent systematic review and meta-analysis of NP pharmacotherapy, supersedes the original guidance and has been reviewed and endorsed by the CPLA panel members as the most up-to-date, appropriate guidance for implementation across Latin America [26] .
• "Diagnosis and treatment of low back pain: A joint clinical practice guideline from the American College of Physicians (ACP) and the American Pain Society (APS)" (2007) [22] . Although these guidelines were deemed the most appropriate, we felt it was important to make practitioners aware of regional issues that may need consideration. Therefore, we present additional advice that was collated as part of the consensus process to optimize guideline implementation (Tables 5 and 6 ). To highlight where regional issues are applicable, we have linked this information to the algorithms derived for each guideline (Figures 1 and 2 ).
It is beyond the scope of this article to discuss the content of each of these guidelines in detail.
Discussion
We reviewed all shortlisted guidelines at length. Reasons for or against final selection were based on the overriding consideration of finding the most appropriate and applicable guidelines from a Latin American perspective.
Our consensus recommendations for NP were the IASP (NeuPSIG) 2015 recommendations [26] ; for CLBP, our recommendation was "Diagnosis and treatment of low back pain: A joint clinical practice guideline from the American College of Physicians (ACP) and the American Pain Society (APS)" (2007) [22] .
The IASP (NeuPSIG) 2015 guidelines were considered the most relevant and practical NP guidelines as they are supported by excellent evidence-based sources and these recommendations have been included in other respected guidelines. Importantly, the IASP (NeuPSIG) recommendations are clear and concise, and therefore easy for primary care practitioners to adapt and adopt. The guidance on when to refer patients to specialists and the stepwise approach to therapy initiation, change of therapy, and therapy combination (Figure 1 ) is considered to be achievable in Latin America. Most of the therapies included in the guidelines are available in at least some Latin American countries, and the document incorporates some guidance on the rational use of analgesic combinations in the management of NP.
The ACP/ACS guidelines were selected because they are practical, evidence based, and include transparent inclusion and exclusion criteria. Although published in 2007, the consensus group agreed that the guidelines remained relevant in light of current treatment practices. The guidelines are concise and unambiguous and include seven key recommendations for the diagnosis Guidelines for the integrated management of musculoskeletal pain symptoms [20] 2008 UK
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Practice guidelines for the management of low back pain [25] 2011 Mexico and treatment of CLBP. They are also sufficiently didactic, including treatment pathways for the initial evaluation and management of patients ( Figure 2 ). We concluded A. Some recommendations do not include diagnostic criteria B. Not all recommended treatments are available in Latin America-in Chile, all drugs mentioned in the guidelines are available; in Peru, amitriptyline is available but desipramine is not; in Colombia, nortriptyline and desipramine are not available C. As pharmacological treatments for NP are often prescribed long-term, physicians must balance pain relief against the risk of side effects D. It is important to be aware of the cardiotoxicity of tricyclic antidepressant drugs when considering their use (e.g., nortriptyline [a standard treatment due to its low cost and relative efficacy], desipramine, and amitriptyline) [26, 27] , and they should not be used in patients age > 65 years with heart conduction disturbances or urinary retention E. Tricyclic drugs are effective when prescribed at low doses and side effects are taken into account F. Health care practitioners should consider use of analgesic combinations earlier to minimize the risk of side effects and manage NP more effectively G. The guidelines do not focus in-depth on nonpharmacological management or management approaches using combination therapies H. Pharmacological therapy may not always be sufficient, and interventional techniques should be considered for some patients I. For practical use in Latin America, nonpharmacological multidisciplinary programs should be included J. It was perceived that regional general practitioners may have become "desensitized" to prescribing treatments for NP and therefore tend to refer to a specialist rather than increase treatment intensity; education and policy change may be required to reverse this trend K. Differences in health care systems and health care practitioners' access to treatments vary between Latin American countries and are partly determined by each country's economy L. Guideline advice is particularly important in countries like Costa Rica, where there are no specialist pain clinics for noncancer pain management M. The importance of ideal weight, exercising to strengthen the low back area, and reducing inactivity to help alleviate CLBP should be emphasized [28] CLBP ¼ chronic low back pain; NP ¼ neuropathic pain. A-N Latin American considerations linked to algorithm in Figure 1 . that the ACP/APS guidelines would be useful for primary care practitioners as they place sufficient emphasis on undertaking a thorough initial physical examination before performing imaging or other tests or starting treatment, thus avoiding unnecessary risks.
During our discussions, we identified a number of specific caveats and regional issues that should be considered when implementing these guidelines (Tables 5 and 6 ). These issues include significant variation in access to drug therapies-some regions have access to a limited range of drugs, some of which may be associated with unfavorable side effect profiles or other characteristics that may impact long-term use [38, 26, 27] . Other limitations can include a lack of specialist clinics, poor prescribing practices, and risk aversion by primary care practitioners.
Regional issues specific to CLBP include the need for initial assessment, imaging studies, and differential diagnosis. We also stress the need for immediate specialist referral for any patient exhibiting red-flag symptoms, and we have included practical guidance on the diagnosis for yellow-flag symptoms that may progress to chronic pain (Table 6 ; Supplementary Figure S1 ).
It should also be noted that the CLBP guidelines do not include guidance on opioid analgesics; thus, we American countries, and only a handful of health care practitioners are trained in these procedures in Colombia and Mexico J. The guidelines do not include opioid analgesics, e.g., buprenorphine, or those recently approved by the FDA, e.g., dual l-opioid agonist/norepinephrine reuptake inhibitor, tapentadol, and lidocaine 5% transdermal patch for low back pain with neuropathic pain in a defined area K. The successful use of opioid therapy has been well demonstrated over the years, with weak opioids like tramadol and strong opioids like buprenorphine and tapentadol proven to be effective in the treatment of CLBP [34, 35] L. In Peru, the use of weak opioids in CLBP management has increased, and primary care practitioners need to make a careful risk assessment before initiating opioid therapy M. The guidelines do not include some pharmacologic options available in certain countries, e.g., metamizol and gabapentin (particularly in cases of radiculopathy) [36] N. The guidelines also omitted pregabalin and the antidepressants amitriptyline, imipramine, and duloxetine O. Tricyclic antidepressants widely available in Europe and North America (e.g., nortriptyline and desipramine) may not be available across all Latin America and should be used with caution due to side effects, particularly cardiotoxicity [27] P. Some treatments are prescribed in certain countries despite an absence of supporting trial-based evidence; e.g., in Colombia patients may receive steroids for radiculopathy [37] Q. An interdisciplinary approach to CLBP management involving a neuropathic component is important, and there is a need to provide guidance on the use of simple tools to diagnose NP in subjects with CLBP R. There are no specific interdisciplinary back rehabilitation centers and no regulated specialist back pain treatment centers in some Latin American countries (e.g., Colombia) Table 5 . *Tertiary amine TCAs amitryptyline, imipramine, and clomipramine should be used with caution in patients older than age 65 years or with existing cardiovascular disease.
† Recommended for peripheral neuropathic pain only. TCA ¼ tricyclic antidepressant.
have included information on their use here based on our experience [39] , US Food and Drug Administration recommendations, and regional trends. In addition, we draw attention to the use of treatments that lack consistent supporting evidence, such as steroids [40] ; similarly, there is also wide variation in the availability of alternative therapies and considerable diversity in the level of regulation of practitioners and access to adequate training schemes across the region [41] .
Because of these issues, there is a need for education and policy change to gain maximal benefit from the selected guideline recommendations, although we note that putting all of the recommendations into practice may be subject to the financial constraints of each local economy.
As an important first step, the guidelines must be made accessible and effectively disseminated to physicians in order to improve clinical practice. To do so, the IASP [26] .
[A-R] refer to Latin America-specific considerations in Table 6 . LBP ¼ low back pain.
(NeuPSIG) 2015 guidelines for NP and the ACP/APS 2007 guidelines for CLBP guidelines, as well as this consensus recommendation, will be translated into Spanish and Portuguese so they can be used by doctors throughout Latin America. Furthermore, CPLA plans to distribute the guidelines through multiple channels, including the CPLA online portal, which provides a repository of publications and educational materials relevant to the management of chronic pain, as well as through professional societies and centers of excellence. In addition, CPLA members and their colleagues will play a key role in fostering the uptake of these recommendations by health care professionals. Finally, CPLA also plans to collaborate with its sponsors to develop and implement a range of educational initiatives, such as preceptorships and workshops, in order to educate health care professionals on the importance of best practice treatment of chronic pain.
In summary, we recommend the implementation of the IASP (NeuPSIG) 2015 guidelines [26] for NP and the ACP/APS 2007 guidelines [22] for CLBP as these are considered the most relevant for Latin America and advise that attention is paid to the local factors that may influence successful implementation of each guideline. We further propose that the current consensus guidelines should be translated into Spanish and Portuguese for ease of access.
Through practical strategies, such as the implementation of universal guidelines, it should be possible to overcome region-specific barriers to best practice and achieve the goal of effective management of patients with chronic pain.
